Dr. Lal PathLabs Limited (LALPATHLAB): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Dr. Lal PathLabs Limited, explained in plain English.

• ▪Dr. Lal PathLabs Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
• ▪LALPATHLAB closed at ₹1,906.40 on 30 October 2026.
• ▪Over the past year the shares are up 23.4%, trading between ₹1,272.60 and ₹2,038.60.
• ▪Reported fundamentals show a net margin of 18.75%, debt to equity of 7.83.
• ▪Our transparent MaxGrade checklist scores it C (64/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 28.58% with a maximum drawdown of -19.65% and a beta of 0.4 against NIFTY 50.
• ▪Recent coverage: Is India’s diagnostics sector poised for a long-term growth upswing? Axis Securities sees opportunity in three stocks

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Last traded values from 30 Oct 2026. Market closed.